Funk J, Langeland T, Schrumpf E, Hanssen L E
Department of Dermatology, Rikshospitalet, Oslo, Norway.
Br J Dermatol. 1991 Nov;125(5):463-5. doi: 10.1111/j.1365-2133.1991.tb14774.x.
Recombinant human interferon-alpha has been used in the treatment of several cancers, but there have been several reports that it may exacerbate psoriasis or trigger off its onset. We report four patients, three of whom first developed psoriasis and one who had an aggravation of the condition during treatment with interferon-alpha. Three of the patients had the carcinoid syndrome and one a renal carcinoma, and all were treated with interferon-alpha 2b or 2a (IFN-alpha 2b, 2a) with doses ranging from 1.5 x 10(6) U daily to 18 x 10(6) U three times weekly. In two of the patients there appeared to be a correlation between the severity of the psoriasis and the dosage of interferon.
重组人α干扰素已用于多种癌症的治疗,但有几份报告称,它可能会加重银屑病或引发其发作。我们报告了4例患者,其中3例首次出现银屑病,1例在使用α干扰素治疗期间病情加重。3例患者患有类癌综合征,1例患有肾癌,所有患者均接受α干扰素2b或2a(IFN-α 2b、2a)治疗,剂量从每日1.5×10⁶单位到每周3次、每次18×10⁶单位不等。在2例患者中,银屑病的严重程度与干扰素剂量之间似乎存在关联。